[{"id":"da-pair-lecanemab-mri","kind":"pairing","name":"Lecanemab with MRI monitoring","aka":[],"tldr":"Amyloid antibodies are used with scheduled MRI checks for ARIA, not as a standalone infusion without imaging follow-up.","summary":"This pairing is a teaching node: the medicine and the scan belong together. It is not a local protocol.","asOf":"2026-09-21","links":[{"label":"FDA Leqembi","url":"https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease"],"sections":[],"technologies":["da-tech-mri"],"targets":[],"drugs":["da-lecanemab"],"companies":[],"institutions":[],"pathways":[],"terms":["da-term-aria"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"a":"da-lecanemab","b":"da-tech-mri","rationale":"ARIA monitoring on MRI is part of using an amyloid antibody, not an optional extra.","evidence":"The US lecanemab label requires MRI monitoring for ARIA. See the FDA approval communication.","pairingType":"diagnostic-therapeutic"}]